EORTC has opened the first site for the #RENALUT study, launching a Phase II evaluation of [177Lu]Lu‑PSMA‑617 in metastatic clear cell renal cell carcinoma after progression on prior treatments. More sites across Europe will follow.

🔗Read more: www.eortc.org/blog/2026/02...

#ccRCC #CancerResearch

📢 New publication alert!

EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.

🔗 www.eortc.org/publications/

#EORTC #RENALUT #ccRCC